Top

Archives of Osteoporosis

Published in:

Open Access 01-12-2023 | Bisphosphonate | Original Article

The osteoporosis treatment gap in Switzerland between 1998 and 2018

Authors: Kurt Lippuner, Bita Yousefi Moghadam, Patrick Schwab

Published in: Archives of Osteoporosis | Issue 1/2023

Abstract

Summary

The annual number of patients treated for osteoporosis between 1998 and 2018 in Switzerland increased until 2008 and steadily decreased thereafter. With a continuously growing population at fracture risk exceeding an intervention threshold, the treatment gap has increased and the incidence of hip fractures has stopped declining in the past decade.

Introduction

The existence of an osteoporosis treatment gap, defined as the percentage of patients at risk for osteoporotic fractures exceeding an intervention threshold but remaining untreated, is widely acknowledged. Between 1998 and 2018, new bone active substances (BAS) indicated for the treatment of osteoporosis became available. Whether and if so to what extent these new introductions have altered the treatment gap is unknown.

Methods

The annual number of patients treated with a BAS was calculated starting from single-drug unit sales. The number of patients theoretically eligible for treatment with a BAS was estimated based on four scenarios corresponding to different intervention thresholds (one based solely on a bone mineral density T score threshold and three FRAX-based thresholds) and the resulting annual treatment gaps were calculated.

Results

In Switzerland, the estimated number of patients on treatment with a BAS increased from 35,901 in year 1998 to 233,381 in year 2018. However, this number grew regularly since 1998, peaked in 2008, and steadily decreased thereafter, in timely coincidence with the launch of intravenous bisphosphonates and the RANKL inhibitor denosumab. When expressed in numbers of untreated persons at risk for osteoporotic fractures exceeding a given intervention threshold, the treatment gaps were of similar magnitude in 1998 (when the first BSAs just had become available) and 2018. There was a strong association, which does not imply causation, between the proportion of patients treated and hip fracture incidence.

Conclusion

In Switzerland, the osteoporosis treatment gap has increased over the past decade. The availability of new BAS has not contributed to its decrease.

Available only for authorised users

(1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1–129

Lippuner K, Johansson H, Kanis JA, Rizzoli R (2009) Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int 20:1131–1140CrossRefPubMed

Lippuner K, Rimmer G, Stuck AK, Schwab P, Bock O (2022) Hospitalizations for major osteoporotic fractures in Switzerland: a long-term trend analysis between 1998 and 2018. Osteoporos Int 33(11):2327–2335CrossRefPubMedPubMedCentral

Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Fracture Intervention Trial Research Group. Lancet 348:1535–1541CrossRefPubMed

Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMed

Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefPubMed

Skjodt MK, Ernst MT, Khalid S et al (2021) The treatment gap after major osteoporotic fractures in Denmark 2005–2014: a combined analysis including both prescription-based and hospital-administered anti-osteoporosis medications. Osteoporos Int 32:1961–1971CrossRefPubMedPubMedCentral

Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O (2017) Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population. Osteoporos Int 28:2485–2494CrossRefPubMedPubMedCentral

Malle O, Borgstroem F, Fahrleitner-Pammer A, Svedbom A, Dimai SV, Dimai HP (2021) Mind the gap: incidence of osteoporosis treatment after an osteoporotic fracture - results of the Austrian branch of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS). Bone 142:115071CrossRefPubMed

10.

Iconaru L, Smeys C, Baleanu F et al (2020) Osteoporosis treatment gap in a prospective cohort of volunteer women. Osteoporos Int 31:1377–1382CrossRefPubMed

11.

Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgstrom F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82CrossRefPubMedPubMedCentral

12.

Singer AJ, Liu J, Yan H, Stad RK, Gandra SR, Yehoshua A (2021) Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage. Osteoporos Int 32:2473–2484CrossRefPubMedPubMedCentral

13.

Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29:2520–2526CrossRefPubMed

14.

Lippuner K, Johansson H, Borgstrom F, Kanis JA, Rizzoli R (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX(R) in Switzerland. Osteoporos Int 23:2579–2589CrossRefPubMed

15.

Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21:381–389CrossRefPubMed

16.

Ferrari S, Lippuner K, Lamy O, Meier C (2020) 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO). Swiss Med Wkly 150:w20352CrossRefPubMed

17.

Svedbom A, Ivergard M, Hernlund E, Rizzoli R, Kanis JA (2014) Epidemiology and economic burden of osteoporosis in Switzerland. Arch Osteoporos 9:187CrossRefPubMed

18.

Chotiyarnwong P, McCloskey EV, Harvey NC et al (2022) Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. Arch Osteoporos 17:87CrossRefPubMedPubMedCentral

19.

Harvey NC, Kanis JA, Liu E, Vandenput L, Lorentzon M, Cooper C, McCloskey E, Johansson H (2021) Impact of population-based or targeted BMD interventions on fracture incidence. Osteoporos Int 32:1973–1979CrossRefPubMed

20.

Koller G, Goetz V, Vandermeer B, Homik J, McAlister FA, Kendler D, Ye C (2020) Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int 31:2093–2102CrossRefPubMed

21.

Tremblay E, Perreault S, Dorais M (2016) Persistence with denosumab and zoledronic acid among older women: a population-based cohort study. Arch Osteoporos 11:30CrossRefPubMed

22.

Borek DM, Smith RC, Gruber CN, Gruber BL (2019) Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study. Osteoporos Int 30:1455–1464CrossRefPubMed

23.

Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031CrossRefPubMed

24.

Whitaker M, Guo J, Kehoe T, Benson G (2012) Bisphosphonates for osteoporosis–where do we go from here? N Engl J Med 366:2048–2051CrossRefPubMed

25.

Rodan G, Reszka A, Golub E, Rizzoli R (2004) Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 20:1291–1300CrossRefPubMed

26.

Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938CrossRefPubMed

27.

Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365–372CrossRefPubMed

28.

Black DM, Reid IR, Boonen S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243–254CrossRefPubMed

29.

Black DM, Kelly MP, Genant HK et al (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761–1771CrossRefPubMed

30.

Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMed

31.

Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, Rizzoli R, Cooper C, Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28:1507–1529CrossRefPubMedPubMedCentral

32.

Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14:571–581CrossRefPubMed

33.

Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943–1951CrossRefPubMed

34.

Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefPubMed

35.

Anderson GL, Limacher M, Assaf AR et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712CrossRefPubMed

36.

Heinig M, Braitmaier M, Haug U (2021) Prescribing of menopausal hormone therapy in Germany: current status and changes between 2004 and 2016. Pharmacoepidemiol Drug Saf 30:462–471CrossRefPubMed

37.

Crawford SL, Crandall CJ, Derby CA, El Khoudary SR, Waetjen LE, Fischer M, Joffe H (2018) Menopausal hormone therapy trends before versus after 2002: impact of the Women’s Health Initiative Study Results. Menopause 26:588–597CrossRefPubMedPubMedCentral

38.

Heiss G, Wallace R, Anderson GL et al (2008) Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299:1036–1045CrossRefPubMed

Title: The osteoporosis treatment gap in Switzerland between 1998 and 2018
Authors: Kurt Lippuner
Bita Yousefi Moghadam
Patrick Schwab
Publication date: 01-12-2023
Publisher: Springer London
Keywords: Bisphosphonate
Osteoporosis
Osteoporosis
Denosumab
Denosumab
Published in: Archives of Osteoporosis / Issue 1/2023
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-022-01206-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The osteoporosis treatment gap in Switzerland between 1998 and 2018

Abstract

Summary

Introduction

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Relationships between sclerostin and morphometric vertebral fractures, bone mineral density, and bone microarchitecture in postmenopausal women

A new FRAX model for Brazil

Prevalence of and risk factors for vertebral fracture and low bone mineral density among Peruvian women aging with HIV

The correlation between circulating growth differentiation factor 11 and the risk of osteopenia/osteoporosis in men

Development of a system to assess the two- and three-dimensional bone mineral density of the lumbar vertebrae from clinical quantitative CT images

Elevated circulating levels of IL-34 are strongly associated with osteoporosis